Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Interaction between aclidinium bromide and formoterol fumarate in small human airways

Mario Cazzola, Luigi Calzetta, Clive P. Page, Paola Rogliani, Francesco Facciolo, Amadeu Gavaldà, Maria Gabriella Matera
European Respiratory Journal 2014 44: P3338; DOI:
Mario Cazzola
1Department of System Medicine, University of Rome ‘Tor Vergata’, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luigi Calzetta
6Department of Respiratory Rehabilitation, San Raffaele Pisana Hospital, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clive P. Page
2Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Rogliani
1Department of System Medicine, University of Rome ‘Tor Vergata’, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Facciolo
3Thoracic Surgery, Regina Elena National Cancer Institute, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amadeu Gavaldà
4R&D Center, Almirall, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Gabriella Matera
5Department of Experimental Medicine, Second University of Naples, Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background

Combining a long-acting β2-agonist (LABA) with a long-acting muscarinic antagonist (LAMA) may improve chronic obstructive pulmonary disease therapy.

Aim

To investigate the synergistic interaction of aclidinium (LAMA) and formoterol (LABA) in small human bronchi.

Methods

Precision cut lung slices (PCLSs) from 8 patients were incubated inKrebs-Henseleit solution (37°C) aerated with O2/CO2 (95:5%). The concentration response to aclidinium and formoterol, administered alone and in combination, at isoeffective concentrations, was assessed at sub-maximal contraction (70% maximum, EC70) induced by acetylcholine (ACh).

PCLS relaxation was expressed as % of maximal response (lumen area enhancement) induced by papaverine (Emax) and potency as the negative logarithm of IC50 or EC50 (pD2). Drug mixture effects were analyzed by Bliss Independence theory. Values (n=3) are mean±SEM.

Results

Aclidinium and formoterol induced potent concentration-dependent relaxation of PCLSs (pD2: aclidinium 7.9±0.3, formoterol 8.4±0.3). Only formoterol eliminated ACh-induced bronchiolar contraction (Emax: formoterol 99.0±5.6%, aclidinium 68.1±4.5%; p<0.05).

Aclidinium and formoterol at low-to-high concentrations (aclidinium 3.2 nM–1.0 µM, formoterol 1.0–63.0 nM) had a synergistic relaxant response on PCLSs, enhancing relaxation by +19.7±0.8% compared with the expected response (p<0.05).

Low concentrations (EC30) of aclidinium with formoterol induced significant (p<0.05) lumen area enhancement; 69.9±2.3% compared with the expected response (51.0±5.6%).

Conclusions

Aclidinium and formoterol had a synergistic interaction on the lumen area enhancement of bronchioles, mainly at low concentrations.

  • Bronchodilators
  • COPD - management
  • Pharmacology
  • © 2014 ERS
Previous
Back to top
Vol 44 Issue Suppl 58 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interaction between aclidinium bromide and formoterol fumarate in small human airways
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Interaction between aclidinium bromide and formoterol fumarate in small human airways
Mario Cazzola, Luigi Calzetta, Clive P. Page, Paola Rogliani, Francesco Facciolo, Amadeu Gavaldà, Maria Gabriella Matera
European Respiratory Journal Sep 2014, 44 (Suppl 58) P3338;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Interaction between aclidinium bromide and formoterol fumarate in small human airways
Mario Cazzola, Luigi Calzetta, Clive P. Page, Paola Rogliani, Francesco Facciolo, Amadeu Gavaldà, Maria Gabriella Matera
European Respiratory Journal Sep 2014, 44 (Suppl 58) P3338;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Omalizumab, airway obstruction and remodeling
  • Central role for the TRPV4-ATP-P2X3 axis in sensory nerve activation and the late asthmatic response
  • Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society